Varieties: | Infectious Disease Prevention Medicine |
---|---|
Component: | Chemical Synthetic Drugs |
Type: | The First Class |
Pharmacodynamic Influential Factors: | Repeated Medication |
Storage Method: | Moisture Proof |
Veterinary Reg. No.: | No |
Samples: |
---|
Suppliers with verified business licenses
Identification | ||
Name | Enrofloxacin | |
Synonyms | 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
Molecular Structure | ||
Molecular Formula | C19H22FN3O3 | |
Molecular Weight | 359.40 | |
CAS Registry Number | 93106-60-6 |
Test Items | Standard |
Appearance | Pale yellowish or light yellow crystalline powder |
Solubility | Practically insoluble in water,freely soluble in methylene chloride,slightly soluble in methanol. |
Identification | IR:Conforms to the spectrum of enrofloxacin CRS |
Appearance of solution | Not more opalescent than reference suspension II and not more intensely coloured reference solution GY4. |
Impurity A | ≤0.2% |
Ralated substance Impurity B Impurity C Unspecified impurity Total impurity |
≤0.5% ≤0.2% ≤0.2% ≤1.0% |
Ralated substances Ethanol Isoamyl alcohol Methanol Toluene N,N-dimethylformaminde |
≤200ppm ≤100ppm ≤200ppm ≤100ppm ≤880ppm |
Loss on drying | ≤1.0% |
Sulphated ash | ≤0.1% |
Heavy metals | ≤ 20 ppm |
Assay(on drying basis) | 98.5%~101.5% |
It is unlikely that an acute overdose of either compound would result in symptoms more serious than either anorexia or vomiting, but the adverse effects noted above could occur. Dogs receiving 10 times the labeled dosage rate of enrofloxacin for at least 14 days developed only vomiting and anorexia. Death did occur in some dogs when fed 25 times the labeled rate for 11 days, however.
Suppliers with verified business licenses